Christian Hesslinger

Biberach An Der Riss, BW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Mass spectrometry-based peripheral blood proteomics for biomarker discovery in idiopathic pulmonary fibrosis.

Mass spectrometry-based peripheral blood proteomics for biomarker discovery in idiopathic pulmonary fibrosis.

Journal: Respiratory research
Published: April 03, 2025

Circulating prostasin is an independent marker of mortality risk in patients with idiopathic pulmonary fibrosis.

Circulating prostasin is an independent marker of mortality risk in patients with idiopathic pulmonary fibrosis.

Journal: ERJ open research
Published: July 24, 2024

Cyclic nucleotide phosphodiesterases as drug targets.

Cyclic nucleotide phosphodiesterases as drug targets.

Journal: Pharmacological reviews
Published: May 30, 2024

Associations of circulating matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases with clinically relevant outcomes in idiopathic pulmonary fibrosis: Data from the IPF-PRO Registry.

Associations of circulating matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases with clinically relevant outcomes in idiopathic pulmonary fibrosis: Data from the IPF-PRO Registry.

Journal: PloS one
Published: April 24, 2024

Utility of the 52-Gene Risk Score to Identify Patients with Idiopathic Pulmonary Fibrosis at Greater Risk of Mortality in the Era of Antifibrotic Therapy.

Utility of the 52-Gene Risk Score to Identify Patients with Idiopathic Pulmonary Fibrosis at Greater Risk of Mortality in the Era of Antifibrotic Therapy.

Journal: Lung
Published: March 18, 2024

Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry.

Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry.

Journal: Respiratory research
Published: June 13, 2023

Corrigendum: BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis.

Corrigendum: BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis.

Journal: Frontiers in pharmacology
Published: May 09, 2023

Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis.

Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis.

Journal: Journal of comparative effectiveness research
Published: December 20, 2022

Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression.

Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression.

Journal: Respiratory research
Published: October 27, 2022

Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis.

Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis.

Journal: The New England journal of medicine
Published: May 15, 2022

Correction to: Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort.

Correction to: Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort.

Journal: Lung
Published: February 15, 2022

BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis.

BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis.

Journal: Frontiers in pharmacology
Published: December 17, 2021
Showing 1-12 of 15

Last Updated: 09/26/2026